Oncology & Cancer

Study provides new drug target for Her-2 related breast cancer

Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene ...

Oncology & Cancer

Study uncovers mutation that supercharges tumor-suppressor

Cancer researchers have long hailed p53, a tumor-suppressor protein, for its ability to keep unruly cells from forming tumors. But for such a highly studied protein, p53 has hidden its tactics well.

Oncology & Cancer

Targeting GITR in cancer immunotherapy

A new research perspective titled "Targeting GITR in cancer immunotherapy—there is no perfect knowledge" has been published in Oncotarget.

Medications

Cometriq approved for rare thyroid cancer

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Oncology & Cancer

Researchers identify gene involved in lung tumor growth

Lung cancer researchers at St. Joseph's Hospital and Medical Center in Phoenix, Ariz., in collaboration with researchers at the Translational Genomics Research Institute and other institutions, have identified a gene that ...

Oncology & Cancer

Cancer metastasis: The unexpected perils of hypoxia

The low oxygen concentrations that prevail in many tumors enhance their propensity to metastasize to other tissues. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich led by Professor Heiko Hermeking have now ...

Oncology & Cancer

Soluble antibodies play immune suppressive role in tumor progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology ...

page 4 from 6